Germany's Jerini is touting half of the results from two pivotal Phase III trials for Icatibant, an experimental subcutaneous treatment of hereditary angioedema (HAE). In one study, the primary endpoint was reached, showing a significant reduction in the time to onset of symptom relief. A second Phase III study, though, failed to hit its primary endpoint. The primary endpoint of median time to onset of symptom relief in the second trial was 2.5 hours for Icatibant versus 4.6 hours for placebo, which was not statistically significant. KOS Pharmaceuticals holds the North American marketing rights to the drug.
- here's the release on the data
PLUS: News of the failure in one of Jerini's trials boosted shares of Dyax, which has a competing drug in development for hereditary angiodema. Report